Clinical Trials on Melanoma Recurrent

Total 9414 results

Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental

United States
Mannkind Corporation

Terminated

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Sohag University

Recruiting

Serum Levels of Vitamin D,Calcium and Magnesium in Preschool Recurrent Wheezers

Recurrent Wheezes

Egypt
Steinar Aamdal

Terminated

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

Norway
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
Universitair Ziekenhuis Brussel

Recruiting

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (DW-MRi)

Melanoma

Belgium
National Cancer Institute (NCI)

Completed

Lovastatin in Treating Patients At High Risk of Melanoma

Precancerous Condition | Stage II Melanoma | Stage 0 Melanoma | Stage I Melanoma

United States
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Syneos Health
Oncolys BioPharma Inc

Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Melanoma Stage Iv | Melanoma Stage III

United States
Sheba Medical Center

Unknown

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Melanoma Stage Iv | Unresectable Stage III Melanoma

Israel
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical Center

Completed

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United States
Mannkind Corporation

Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Advanced Melanoma | Stage III and IV Melanoma

United States
Inge Marie Svane
Adaptimmune

Not yet recruiting

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (ADP-TILIL7)

Melanoma | Melanoma Stage IV | Melanoma Stage III
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Stage IV Melanoma | Stage III Melanoma

United States
Lisata Therapeutics, Inc.

Terminated

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
Medical University of Vienna

Completed

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

Austria
Al Baraka Fertility Hospital

Recruiting

Role of Atosiban in Recurrent Implantation Failure (RIF)

Recurrent Implantation Failure

Bahrain
Universitaire Ziekenhuizen KU Leuven

Completed

Incidence of Recurrent Caries Next to Tooth Restorations

Recurrent Caries

Belgium
Sprim Advanced Life Sciences
The National Institute of Probiotics

Unknown

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

Recurrent Gastrointestinal Symptoms

United States
Instituto de Olhos de Goiania

Completed

Phototherapeutic Keratectomy (PTK) on Recurrent Corneal Erosions (PTK x CE)

Recurrent Corneal Erosions
Grupo Español Multidisciplinar de Melanoma

Recruiting

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (GEM-1801)

Advanced Cancer | Melanoma Stage Iv | Melanoma Stage Iii

Spain
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Jewish General Hospital

Active, not recruiting

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

Untreated Stage III Melanoma or Stage IV Melanoma

Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
TransMolecular

Terminated

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Melanoma | Metastatic Melanoma | Malignant Melanoma

United States
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Amgen

Completed

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Unresectable Stage IIIB-IV Malignant Melanoma

Japan
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
Pierre Fabre Medicament
Biotrial

Completed

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma

Stage IIIC Skin Melanoma | Stage IV Melanoma

United States
St. Louis University

Completed

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel)

Melanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III Melanoma

United States

Clinical Trials on Melanoma Recurrent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations